Literature DB >> 25316178

Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma.

Collette R Lessard-Anderson1, Kathryn S Handlogten2, Rochelle J Molitor3, Sean C Dowdy4, William A Cliby5, Amy L Weaver6, Jennifer St Sauver7, Jamie N Bakkum-Gamez8.   

Abstract

OBJECTIVE: To determine the effect of excisional tubal sterilization on subsequent development of serous epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC).
METHODS: We performed a population-based, nested case-control study using the Rochester Epidemiology Project. We identified all patients with a diagnosis of serous EOC or PPC from 1966 through 2009. Each case was age-matched to 2 controls without either diagnosis. Odds ratios (ORs) and corresponding 95% CIs were estimated from conditional logistic regression models. Models were adjusted for prior hysterectomy, prior salpingo-oophorectomy, oral contraceptive use, endometriosis, infertility, gravidity, and parity.
RESULTS: In total, we identified 194 cases of serous EOC and PPC during the study period and matched them with 388 controls (mean [SD] age, 61.4 [15.2] years). Fourteen cases (7.2%) and 46 controls (11.9%) had undergone tubal sterilization. Adjusted risk of serous EOC or PPC was slightly lower after any tubal sterilization (OR, 0.59 [95% CI, 0.29-1.17]; P=.13). The rate of excisional tubal sterilization was lower in cases than controls (2.6% vs 6.4%). Adjusted risk of serous EOC and PPC was decreased by 64% after excisional tubal sterilization (OR, 0.36 [95% CI, 0.13-1.02]; P=.054) compared with those without sterilization or with nonexcisional tubal sterilization.
CONCLUSIONS: We present a population-based investigation of the effects of excisional tubal sterilization on the risk of serous EOC and PPC. Excisional methods may confer greater risk reduction than other sterilization methods.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fimbriectomy; Salpingectomy; Serous ovarian cancer; Serous primary peritoneal cancer; Tubal sterilization

Mesh:

Year:  2014        PMID: 25316178      PMCID: PMC4268072          DOI: 10.1016/j.ygyno.2014.10.005

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  36 in total

1.  Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study.

Authors:  Antonis C Antoniou; Matti Rookus; Nadine Andrieu; Richard Brohet; Jenny Chang-Claude; Susan Peock; Margaret Cook; D Gareth Evans; Rosalind Eeles; Catherine Nogues; Laurence Faivre; Paul Gesta; Flora E van Leeuwen; Margreet G E M Ausems; Ana Osorio; Trinidad Caldes; Jacques Simard; Jan Lubinski; Anne-Marie Gerdes; Edith Olah; Christine Fürhauser; Hakan Olsson; Brita Arver; Paolo Radice; Douglas F Easton; David E Goldgar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-03       Impact factor: 4.254

2.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

Review 3.  Underlying mechanisms of ovarian cancer risk reduction after tubal ligation.

Authors:  David Cibula; Martin Widschwendter; Michael Zikan; Ladislav Dusek
Journal:  Acta Obstet Gynecol Scand       Date:  2011-04-15       Impact factor: 3.636

Review 4.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Hum Pathol       Date:  2011-07       Impact factor: 3.466

5.  High-grade serous ovarian cancer arises from fallopian tube in a mouse model.

Authors:  Jaeyeon Kim; Donna M Coffey; Chad J Creighton; Zhifeng Yu; Shannon M Hawkins; Martin M Matzuk
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-13       Impact factor: 11.205

6.  Hydrosalpinx and IVF outcome: cumulative results after salpingectomy in a randomized controlled trial.

Authors:  A Strandell; A Lindhard; U Waldenström; J Thorburn
Journal:  Hum Reprod       Date:  2001-11       Impact factor: 6.918

7.  BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?

Authors:  Ilana Cass; Christine Holschneider; Nandini Datta; Denise Barbuto; Ann E Walts; Beth Y Karlan
Journal:  Obstet Gynecol       Date:  2005-12       Impact factor: 7.661

8.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

Review 9.  Prophylactic oophorectomy in premenopausal women and long-term health.

Authors:  Lynne T Shuster; Bobbie S Gostout; Brandon R Grossardt; Walter A Rocca
Journal:  Menopause Int       Date:  2008-09

10.  Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies.

Authors:  Weiva Sieh; Shannon Salvador; Valerie McGuire; Rachel Palmieri Weber; Kathryn L Terry; Mary Anne Rossing; Harvey Risch; Anna H Wu; Penelope M Webb; Kirsten Moysich; Jennifer A Doherty; Anna Felberg; Dianne Miller; Susan J Jordan; Marc T Goodman; Galina Lurie; Jenny Chang-Claude; Anja Rudolph; Susanne Krüger Kjær; Allan Jensen; Estrid Høgdall; Elisa V Bandera; Sara H Olson; Melony G King; Lorna Rodriguez-Rodriguez; Lambertus A Kiemeney; Tamara Marees; Leon F Massuger; Anne M van Altena; Roberta B Ness; Daniel W Cramer; Malcolm C Pike; Celeste Leigh Pearce; Andrew Berchuck; Joellen M Schildkraut; Alice S Whittemore
Journal:  Int J Epidemiol       Date:  2013-04       Impact factor: 7.196

View more
  24 in total

Review 1.  Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention.

Authors:  Anthony N Karnezis; Kathleen R Cho
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

2.  Women's preferences for permanent contraception method and willingness to be randomized for a hypothetical trial.

Authors:  Adriana Piazza; Kelly Schwirian; Fiona Scott; Machelle D Wilson; Nikki B Zite; Mitchell D Creinin
Journal:  Contraception       Date:  2018-09-26       Impact factor: 3.375

Review 3.  Update on permanent contraception options for women.

Authors:  Eva Patil; Jeffrey T Jensen
Journal:  Curr Opin Obstet Gynecol       Date:  2015-12       Impact factor: 1.927

4.  High-grade serous ovarian cancer 3 years after bilateral salpingectomy: A case report.

Authors:  Emi Sato; Kentaro Nakayama; Masako Ishikawa; Kohei Nakamura; Tomoka Ishibashi; Satoru Kyo
Journal:  Mol Clin Oncol       Date:  2016-12-12

5.  An Orthotopic Murine Model of Peritoneal Carcinomatosis of Ovarian Origin for Intraoperative PDT.

Authors:  Thierry Michy; Claire Bernard; Jean-Luc Coll; Véronique Josserand
Journal:  Methods Mol Biol       Date:  2022

Review 6.  Options in Prophylactic Surgery to Prevent Ovarian Cancer in High-Risk Women: How New Hypotheses of Fallopian Tube Origin Influence Recommendations.

Authors:  Casey L Swanson; Jamie N Bakkum-Gamez
Journal:  Curr Treat Options Oncol       Date:  2016-05

7.  A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants.

Authors:  Sehee Kim; Miao Wang; Jonathan P Tyrer; Allan Jensen; Ashley Wiensch; Gang Liu; Alice W Lee; Roberta B Ness; Maxwell Salvatore; Shelley S Tworoger; Alice S Whittemore; Hoda Anton-Culver; Weiva Sieh; Sara H Olson; Andrew Berchuck; Ellen L Goode; Marc T Goodman; Jennifer Anne Doherty; Georgia Chenevix-Trench; Mary Anne Rossing; Penelope M Webb; Graham G Giles; Kathryn L Terry; Argyrios Ziogas; Renée T Fortner; Usha Menon; Simon A Gayther; Anna H Wu; Honglin Song; Angela Brooks-Wilson; Elisa V Bandera; Linda S Cook; Daniel W Cramer; Roger L Milne; Stacey J Winham; Susanne K Kjaer; Francesmary Modugno; Pamela J Thompson; Jenny Chang-Claude; Holly R Harris; Joellen M Schildkraut; Nhu D Le; Nico Wentzensen; Britton Trabert; Estrid Høgdall; David Huntsman; Malcolm C Pike; Paul D P Pharoah; Celeste Leigh Pearce; Bhramar Mukherjee
Journal:  Int J Cancer       Date:  2019-01-20       Impact factor: 7.396

Review 8.  Risk-reducing salpingectomy: Let us be opportunistic.

Authors:  Kara C Long Roche; Nadeem R Abu-Rustum; Mlica Nourmoussavi; Oliver Zivanovic
Journal:  Cancer       Date:  2017-03-23       Impact factor: 6.860

9.  Hysterectomy with opportunistic salpingectomy versus hysterectomy alone.

Authors:  Laura A M van Lieshout; Miranda P Steenbeek; Joanne A De Hullu; M Caroline Vos; Saskia Houterman; Jack Wilkinson; Jurgen Mj Piek
Journal:  Cochrane Database Syst Rev       Date:  2019-08-28

10.  Comparing options for females seeking permanent contraception in high resource countries: a systematic review.

Authors:  Rebecca Gormley; Brian Vickers; Brooke Cheng; Wendy V Norman
Journal:  Reprod Health       Date:  2021-07-20       Impact factor: 3.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.